Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry
ABSTRACT: Objectives: The aim of this study was to analyze whether subgroups of immunosuppressive (IS) medications conferred different outcomes in COVID-19. Methods: The study involved a multicenter retrospective cohort of consecutive immunosuppressed patients (ISPs) hospitalized with COVID-19 from March to July, 2020. The primary outcome was in-hospital mortality. A propensity score-matched (PSM) model comparing ISP and non-ISP was planned, as well as specific PSM models comparing individual IS medications associated with mortality. Results: Out of 16 647 patients, 868 (5.2%) were on chronic IS therapy prior to admission and were considered ISPs. In the PSM model, ISPs had greater in-hospital mortality (OR 1.25, 95% CI 0.99–1.62), which was related to a worse outcome associated with chronic corticoids (OR 1.89, 95% CI 1.43–2.49). Other IS drugs had no repercussions with regard to mortality risk (including calcineurin inhibitors (CNI); OR 1.19, 95% CI 0.65–2.20). In the pre-planned specific PSM model involving patients on chronic IS treatment before admission, corticosteroids were associated with an increased risk of mortality (OR 2.34, 95% CI 1.43–3.82). Conclusions: Chronic IS therapies comprise a heterogeneous group of drugs with different risk profiles for severe COVID-19 and death. Chronic systemic corticosteroid therapy is associated with increased mortality. On the contrary, CNI and other IS treatments prior to admission do not seem to convey different outcomes..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 116(2022), Seite 51-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jorge Calderón-Parra [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Autoimmune diseases |
|---|
| doi: |
10.1016/j.ijid.2021.12.327 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ01372715X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ01372715X | ||
| 003 | DE-627 | ||
| 005 | 20230310060600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.12.327 |2 doi | |
| 035 | |a (DE-627)DOAJ01372715X | ||
| 035 | |a (DE-599)DOAJa341831f21d54f24a3a1b5d855589339 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Jorge Calderón-Parra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT: Objectives: The aim of this study was to analyze whether subgroups of immunosuppressive (IS) medications conferred different outcomes in COVID-19. Methods: The study involved a multicenter retrospective cohort of consecutive immunosuppressed patients (ISPs) hospitalized with COVID-19 from March to July, 2020. The primary outcome was in-hospital mortality. A propensity score-matched (PSM) model comparing ISP and non-ISP was planned, as well as specific PSM models comparing individual IS medications associated with mortality. Results: Out of 16 647 patients, 868 (5.2%) were on chronic IS therapy prior to admission and were considered ISPs. In the PSM model, ISPs had greater in-hospital mortality (OR 1.25, 95% CI 0.99–1.62), which was related to a worse outcome associated with chronic corticoids (OR 1.89, 95% CI 1.43–2.49). Other IS drugs had no repercussions with regard to mortality risk (including calcineurin inhibitors (CNI); OR 1.19, 95% CI 0.65–2.20). In the pre-planned specific PSM model involving patients on chronic IS treatment before admission, corticosteroids were associated with an increased risk of mortality (OR 2.34, 95% CI 1.43–3.82). Conclusions: Chronic IS therapies comprise a heterogeneous group of drugs with different risk profiles for severe COVID-19 and death. Chronic systemic corticosteroid therapy is associated with increased mortality. On the contrary, CNI and other IS treatments prior to admission do not seem to convey different outcomes. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a immunocompromised host | |
| 650 | 4 | |a prognosis factors | |
| 650 | 4 | |a solid organ transplantation | |
| 650 | 4 | |a autoimmune diseases | |
| 650 | 4 | |a immune-mediated inflammatory diseases | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Valentín Cuervas-Mons |e verfasserin |4 aut | |
| 700 | 0 | |a Victor Moreno-Torres |e verfasserin |4 aut | |
| 700 | 0 | |a Manuel Rubio-Rivas |e verfasserin |4 aut | |
| 700 | 0 | |a Paloma Agudo-de Blas |e verfasserin |4 aut | |
| 700 | 0 | |a Blanca Pinilla-Llorente |e verfasserin |4 aut | |
| 700 | 0 | |a Cristina Helguera-Amezua |e verfasserin |4 aut | |
| 700 | 0 | |a Nicolás Jiménez-García |e verfasserin |4 aut | |
| 700 | 0 | |a Paula-María Pesqueira-Fontan |e verfasserin |4 aut | |
| 700 | 0 | |a Manuel Méndez-Bailón |e verfasserin |4 aut | |
| 700 | 0 | |a Arturo Artero |e verfasserin |4 aut | |
| 700 | 0 | |a Noemí Gilabert |e verfasserin |4 aut | |
| 700 | 0 | |a Fátima Ibánez-Estéllez |e verfasserin |4 aut | |
| 700 | 0 | |a Santiago-Jesús Freire-Castro |e verfasserin |4 aut | |
| 700 | 0 | |a Carlos Lumbreras-Bermejo |e verfasserin |4 aut | |
| 700 | 0 | |a Juan-Miguel Antón-Santos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 116(2022), Seite 51-58 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:116 |g year:2022 |g pages:51-58 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2021.12.327 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/a341831f21d54f24a3a1b5d855589339 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971221012224 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 116 |j 2022 |h 51-58 | ||